Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Revolutionary Free COI Tool by TrustLayer Improves Efficiency
-
Deepcoin Launches Futuristic Website & App Redesign to Power a High-Performance Trading Experience
-
Thyme Care Triples Its Multidisciplinary Care Team with Increased Focus on Often-Overlooked Survivorship Population
-
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Introducing Artisan Bakery: A New Family of Innovative Baking Brands Launches at IDDBA 2025
-
EKOUAER Launches Wedding Season Special Edition and Joins The Knot Registry
-
OPPO and the UEFA Champions League Final: Powering Football Innovation On and Off the Pitch
-
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics
-
Green Edge Computing Corp (GECCO) and Capzul Technologies Launch End-to-End Cybersecurity on Rugged Edge Computing Appliance
-
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris
-
Mining Without Machines: ZA Miner Launches Seamless Cloud Solution for Daily Crypto Rewards
-
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Treace Medical
-
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bakkt Holdings
-
Yunpeng Zhao Contributes to U.S. Risk Management System Advancing Financial Stability and Regulatory Efficiency
-
DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer
-
Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis
-
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen
-
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
-
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Elevance
-
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Compass Diversified
-
ZA Miner Launches An AI-Driven Mining Protocol Ensuring Users Earn the Highest Crypto Rewards
-
Announcing Balaji Karumanchi as Founder & CEO of Excelhire – The AI-Agentic Hiring Intelligence Platform
-
Introducing Tempus One in the EHR with Integrated Guidelines
-
Breaking the Paycheck-to-Paycheck Cycle: Bitcoin Solaris Presale Phase 5 Ends in Hours—Mobile Mining App Nears Launch
-
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology
-
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Civitas Resources
-
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of West Pharmaceutical Services
-
Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer
-
IMFINZI® (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
-
Strengthening Vietnam-US business partnership in the agricultural sector: Towards sustainable development and trade balance
-
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Po
-
China Liberal Education Holdings Limited Announces Suspension of Nasdaq Trading
-
Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
-
Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025
-
Research Presented by The US Oncology Network at ASCO 2025 Demonstrates Significant Cost Savings in Community Oncology Setting with Pharmacist-Driven Interventions
-
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Krispy Kreme
-
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon
-
Transform Your Workspace: Madison Liquidators Announces $5,000 Office Makeover Giveaway
-
In New Awareness Campaign, Yara Shahidi Reflects on Growth, Education, and Pursuing Passion
-
Kelly Buick GMC receives 25 Year Dealer Award for GMC
-
Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults
-
Sancrox Political Advisory: Voters rally around Oyun-Erdene ahead of vote of no confidence
-
Blokees made its debut at CCXP México 2025, Officially Enters México Market
-
RDDT INVESTIGATION ALERT: Reddit, Inc. Investors with Losses are Notified to Contact BFA Law about the Pending Securities Fraud Investigation
-
IOVA CLASS ALERT: Iovance Biotherapeutics, Inc. Investors with Losses are Notified to Contact BFA Law about the Securities Fraud Class Action
-
VTRS CLASS ALERT: Viatris Inc. Investors with Losses are Notified to Contact BFA Law before Tuesday's June 3 Securities Fraud Class Action Deadline
-
OGN CLASS ALERT: Organon & Co. Investors with Losses are Notified to Contact BFA Law about the Securities Fraud Class Action
-
ELV CLASS ALERT: Elevance Health, Inc. Investors with Losses are Notified to Contact BFA Law about the Securities Fraud Class Action
-
CODI CLASS ALERT: Compass Diversified Holdings Investors with Losses are Notified to Contact BFA Law about the Securities Fraud Class Action
-
CIVI CLASS ALERT: Civitas Resources, Inc. Investors with Losses are Notified to Contact BFA Law about the Securities Fraud Class Action
